Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2015 · 10-Q
Revenue$194.00K$194.00K— vs Q1 2014 Net Income-$46.43M-$46.43MN/M vs Q1 2014 EPS Diluted-$0.67-$0.67N/M vs Q1 2014 Operating Income-$22,831,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Free Cash Flowderived-$18,715,000N/M Margins · derivedOperating margin-11768.6%
Net margin-23934.5%
ended Mar 31, 2015 · filed May 11, 2015 · 41 d after period end